In the newly diagnosed melanoma cases, all exhibited TMB-High, the ultraviolet signature of this tumor type, which predicts responsiveness to anti-PD-1 and PD-L1 inhibitors otherwise known as ICIs68,69. This evidence concerns the gene CD274 and melanoma.